{"id":"NCT02160145","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","officialTitle":"A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2017-04-18","completion":"2017-04-18","firstPosted":"2014-06-10","resultsPosted":"2018-08-08","lastUpdate":"2018-08-08"},"enrollment":1370,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","Autosomal Dominant Polycystic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Tolvaptan (OPC-41061)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tolvaptan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)","primaryOutcome":{"measure":"The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.","timeFrame":"Pretreatment baseline to post-treatment follow-up (up to 61 weeks).","effectByArm":[{"arm":"Tolvaptan","deltaMin":-2.339,"sd":0.24},{"arm":"Placebo","deltaMin":-3.61,"sd":0.24}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":230,"countries":["United States","Argentina","Australia","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Norway","Poland","Puerto Rico","Romania","Russia","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["39356039","37250503","36191725","31014270","29105594"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":1491},"commonTop":["Polyuria","Thirst","Nocturia","Renal pain","Viral upper respiratory tract infection"]}}